Blood Vessels, Thrombosis & Hemostasis最新文献

{"title":"ECMO-induced coagulopathy: strategic initiatives for research and clinical practice (a workshop report of the NHLBI)","authors":"Jerrold H. Levy ,&nbsp;Peta M. A. Alexander ,&nbsp;Alisa S. Wolberg ,&nbsp;Owen J. T. McCarty ,&nbsp;Anthony E. Pusateri ,&nbsp;Raquel R. Bartz ,&nbsp;Wolfgang Bergmeier ,&nbsp;Mitchell J. Cohen ,&nbsp;Jean M. Connors ,&nbsp;James H. Morrissey ,&nbsp;Matthew D. Neal ,&nbsp;Elisabeth T. Tracy ,&nbsp;Keith McCrae ,&nbsp;Bruce A. Sullenger","doi":"10.1016/j.bvth.2025.100064","DOIUrl":"10.1016/j.bvth.2025.100064","url":null,"abstract":"<div><h3>Abstract</h3><div>In May 2024, the Division of Blood Diseases and Resources of the National Heart, Lung, and Blood Institute (NHLBI) hosted a hybrid workshop on “Extracorporeal membrane oxygenation (ECMO)-induced coagulopathy: strategic initiatives for research and clinical practice.” The event brought together clinicians, scientists, bioengineers, and policymakers to address the challenges of ECMO-associated coagulopathy and explore novel therapeutic approaches. Through expert presentations and collaborative discussions, the workshop focused on innovative anticoagulation strategies, precision medicine, and advanced diagnostics to enhance patient care. The discussions also identified critical research gaps and opportunities for future interdisciplinary collaboration. This summary reviews the current state of knowledge and outlines future research directions for improving ECMO-induced coagulopathy management.</div></div>","PeriodicalId":100190,"journal":{"name":"Blood Vessels, Thrombosis & Hemostasis","volume":"2 2","pages":"Article 100064"},"PeriodicalIF":0.0,"publicationDate":"2025-05-01","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"","citationCount":null,"resultStr":null,"platform":"Semanticscholar","paperid":"143887158","PeriodicalName":null,"FirstCategoryId":null,"ListUrlMain":null,"RegionNum":0,"RegionCategory":"","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":"","EPubDate":null,"PubModel":null,"JCR":null,"JCRName":null,"Score":null,"Total":0}

{"title":"Bender MT, Aggarwal A, Godwin M, et al. Cellular and enzymatic features of thrombi in humans are vascular bed dependent. Blood Vessels Thromb Hemost. 2025;2(1):100029.","authors":"","doi":"10.1016/j.bvth.2025.100057","DOIUrl":"10.1016/j.bvth.2025.100057","url":null,"abstract":"","PeriodicalId":100190,"journal":{"name":"Blood Vessels, Thrombosis & Hemostasis","volume":"2 2","pages":"Article 100057"},"PeriodicalIF":0.0,"publicationDate":"2025-05-01","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"","citationCount":null,"resultStr":null,"platform":"Semanticscholar","paperid":"143894832","PeriodicalName":null,"FirstCategoryId":null,"ListUrlMain":null,"RegionNum":0,"RegionCategory":"","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":"","EPubDate":null,"PubModel":null,"JCR":null,"JCRName":null,"Score":null,"Total":0}

{"title":"Japanese database analysis: effectiveness of early initiation of TPO-RA treatment in tapering corticosteroid dose in ITP","authors":"Kodai Suzuki ,&nbsp;Satoru Ito ,&nbsp;Stefano Carini ,&nbsp;Mami Shimizu ,&nbsp;Shigeki Hatanaka ,&nbsp;Yoshitaka Miyakawa","doi":"10.1016/j.bvth.2025.100066","DOIUrl":"10.1016/j.bvth.2025.100066","url":null,"abstract":"<div><h3>Abstract</h3><div>This longitudinal, descriptive study investigated the effect of the timing of thrombopoietin receptor agonist (TPO-RA) initiation on corticosteroid administration and related adverse events (AEs) in patients with immune thrombocytopenia (ITP) in Japan using real-world data from a health claim database. In total, 7696 patients were divided into 3 groups (early TPO-RA initiation, late TPO-RA initiation, and non–TPO-RA administration) by the presence and timing of TPO-RA administration. The early TPO-RA initiation group included patients first administered TPO-RA &lt;60, &lt;120, and &lt;180 days after the index date. The late TPO-RA initiation group included patients first administered TPO-RA ≥60, ≥120, and ≥180 days after the index date. The early TPO-RA initiation group received the highest daily average prednisolone dose, followed by a rapid decrease in dose, similar to that in the non–TPO-RA administration group. In the early TPO-RA initiation group, there was a long-term trend toward daily average prednisolone doses of ≤5 mg, and by approximately 10 to 11 months, the median dose was 0 mg. Diabetes (insulin-dependent) and hypertension tended to occur more frequently in the late TPO-RA (8.4% and 19.9%, respectively) than in the early TPO-RA initiation group (6.9% and 14.4%, respectively). Incidence rates of infections in the late TPO-RA and early TPO-RA initiation groups were similar (7.2% vs 7.6%). The incidence of AEs was similar between male and female patients; a trend toward a higher incidence was observed in those aged ≥60 years. Early initiation of TPO-RA administration can contribute to reducing total prednisolone dosage, treatment duration, and AEs (eg, hypertension and insulin-dependent diabetes).</div></div>","PeriodicalId":100190,"journal":{"name":"Blood Vessels, Thrombosis & Hemostasis","volume":"2 2","pages":"Article 100066"},"PeriodicalIF":0.0,"publicationDate":"2025-03-24","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"","citationCount":null,"resultStr":null,"platform":"Semanticscholar","paperid":"143858976","PeriodicalName":null,"FirstCategoryId":null,"ListUrlMain":null,"RegionNum":0,"RegionCategory":"","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":"","EPubDate":null,"PubModel":null,"JCR":null,"JCRName":null,"Score":null,"Total":0}

{"title":"D-dimer after 3 months of anticoagulation therapy and outcomes in cancer-associated isolated distal deep vein thrombosis","authors":"Tatsuya Nishikawa ,&nbsp;Yugo Yamashita ,&nbsp;Masashi Fujita ,&nbsp;Takeshi Morimoto ,&nbsp;Nao Muraoka ,&nbsp;Michihisa Umetsu ,&nbsp;Yuji Nishimoto ,&nbsp;Takuma Takada ,&nbsp;Yoshito Ogihara ,&nbsp;Nobutaka Ikeda ,&nbsp;Kazunori Otsui ,&nbsp;Daisuke Sueta ,&nbsp;Yukari Tsubata ,&nbsp;Masaaki Shoji ,&nbsp;Ayumi Shikama ,&nbsp;Yutaka Hosoi ,&nbsp;Yasuhiro Tanabe ,&nbsp;Ryuki Chatani ,&nbsp;Kengo Tsukahara ,&nbsp;Naohiko Nakanishi ,&nbsp;Takeshi Kimura","doi":"10.1016/j.bvth.2025.100063","DOIUrl":"10.1016/j.bvth.2025.100063","url":null,"abstract":"<div><h3>Abstract</h3><div>Cancer-associated isolated distal deep vein thrombosis (IDDVT) is a common complication in patients with cancer. The Optimal Duration of Anticoagulation Therapy for Isolated Distal Deep Vein Thrombosis in Patients with Cancer study revealed the superiority of 12- over 3-month edoxaban treatment with respect to thrombotic risk. However, it remains unclear whether D-dimer levels during anticoagulation influence the efficacy of extended anticoagulation. In this post hoc subgroup analysis, we stratified 519 patients into the low D-dimer (&lt;1.0 μg/mL) (n = 308) and high D-dimer (≥1.0 μg/mL) (n = 211) subgroups based on D-dimer levels at 3 months. The cumulative incidence of a composite of symptomatic recurrent venous thromboembolism (VTE) or VTE-related death was lower in the 12-month edoxaban group than in the 3-month edoxaban group in both the low D-dimer (0.8% vs 5.6%; <em>P</em> = .02; odds ratio [OR], 0.12; 95% confidence interval [CI], 0.01-0.66) and high D-dimer (0.9% vs 10.2%; <em>P</em> = .01; OR, 0.11; 95% CI, 0.01-0.62) subgroups without interaction. Furthermore, there was no significant difference in the cumulative incidence of major bleeding between the 12- and 3-month groups in both the low D-dimer (3.6% vs 1.8%; <em>P</em> = .64; OR, 1.96; 95% CI, 0.47-9.67) and high D-dimer (18.3% vs 14.6%; <em>P</em> = .29; OR, 1.27; 95% CI, 0.60-2.75) subgroups without interaction. In conclusion, a 12-month edoxaban treatment for cancer-associated IDDVT was superior to a 3-month treatment in reducing thrombotic events, irrespective of D-dimer levels after 3 months of anticoagulation therapy. There was no significant increased risk of major bleeding in the 12-month edoxaban group relative to the 3-month edoxaban group regardless of the D-dimer levels at 3 months. This trial was registered at <span><span>www.clinicaltrials.gov</span><svg><path></path></svg></span> as #NCT03895502.</div></div>","PeriodicalId":100190,"journal":{"name":"Blood Vessels, Thrombosis & Hemostasis","volume":"2 2","pages":"Article 100063"},"PeriodicalIF":0.0,"publicationDate":"2025-02-24","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"","citationCount":null,"resultStr":null,"platform":"Semanticscholar","paperid":"143790839","PeriodicalName":null,"FirstCategoryId":null,"ListUrlMain":null,"RegionNum":0,"RegionCategory":"","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":"OA","EPubDate":null,"PubModel":null,"JCR":null,"JCRName":null,"Score":null,"Total":0}

{"title":"Acquired (autoimmune) hemophilia: demographics, outcomes, and readmissions","authors":"Aditi Sharma ,&nbsp;Nikhil Vojjala ,&nbsp;Vijendra Singh","doi":"10.1016/j.bvth.2025.100062","DOIUrl":"10.1016/j.bvth.2025.100062","url":null,"abstract":"<div><h3>Abstract</h3><div>Acquired hemophilia (AHA) is a rare bleeding disorder characterized by autoantibodies against coagulation factors. It predominantly affects older adults and is associated with autoimmune disorders or malignancies. Achieving hemostasis and inhibiting autoantibody production through immunosuppression are the mainstays of treatment.We conducted a retrospective cohort study using the Nationwide Readmissions Database from 2016 to 2019 to perform a descriptive analysis of AHA, including the estimation of the 30-day readmission rate and primary diagnoses at readmission.Of 1450 admissions for AHA, 803 (55.4%) were male, and the median age at admission was 73 years. Approximately 21% had an underlying solid malignancy, 3.9% had hematologic malignancy, and 13.5% had autoimmune disease. Acute myocardial infarction occurred in 9.5%, disseminated intravascular coagulation in 1.2%, intracranial hemorrhage in 1.5%, ischemic stroke in 2.5%, and venous thromboembolism in 4.4%. Bleeding occurred in 30.2% of admissions, with 27% requiring blood transfusion. The median length of hospital stay was 7 days, and there were 101 deaths during the index admission, resulting in a 7% inpatient mortality rate. Mortality was higher in the older age group at 8% compared with 3% in those aged &lt;65 years (<em>P</em> = .03). The 30-day readmission rate was 27%, with a 10.8% mortality rate during readmission. Infections followed by bleeding were the most common causes for readmission. High rates of bleeding and thrombotic complications are seen in AHA, with bleeding and infection being the primary reasons for the elevated 30-day readmission rate, indicating significant treatment-related toxicity and disease relapse.</div></div>","PeriodicalId":100190,"journal":{"name":"Blood Vessels, Thrombosis & Hemostasis","volume":"2 2","pages":"Article 100062"},"PeriodicalIF":0.0,"publicationDate":"2025-02-16","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"","citationCount":null,"resultStr":null,"platform":"Semanticscholar","paperid":"143790838","PeriodicalName":null,"FirstCategoryId":null,"ListUrlMain":null,"RegionNum":0,"RegionCategory":"","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":"OA","EPubDate":null,"PubModel":null,"JCR":null,"JCRName":null,"Score":null,"Total":0}

{"title":"Prevalence of cardiovascular risk factors in persons with venous thromboembolism aged 50 years or younger","authors":"Eng Soo Yap ,&nbsp;Frits R. Rosendaal ,&nbsp;Suzanne C. Cannegieter ,&nbsp;L. J. J. Scheres","doi":"10.1016/j.bvth.2025.100059","DOIUrl":"10.1016/j.bvth.2025.100059","url":null,"abstract":"<div><h3>Abstract</h3><div>The risk of cardiovascular disease (CVD) is elevated in individuals with a history of venous thromboembolism (VTE). It is uncertain whether younger patients, aged ≤50 years, have an increased prevalence of potentially modifiable CVD risk factors, which could be targeted for prevention. We aimed to estimate the prevalence of potentially modifiable CVD risk factors (ie, overweight/obesity, smoking, alcohol use, physical inactivity, hypertension, diabetes mellitus, and dyslipidemia) in persons aged ≤50 years with a history of VTE (cases) and compare with those without VTE (controls). Using data from the Multiple Environmental and Genetic Assessment of risk factors for venous thrombosis case-control study comprising 2627 case patients with first VTE and 1908 random digit dialing control patients, all aged ≤50 years, we estimated the prevalence of risk factors. Analyses were stratified by sex and were performed separately for unprovoked and provoked events. The prevalence of hypertension, diabetes, dyslipidemia, and excessive alcohol intake was low and similar between case and control patients. The prevalence of overweight and obesity, sedentary behavior, and current smoking was higher in case than control patients. When stratified for sex, obesity was highest in women: 24.9% in case vs 9.9% in control patients. Sedentary behavior was more common in case patients than control patients: women, 57.8% vs 41.1%; and men, 48.7% vs 41.5%, respectively. In persons aged ≤50 years with recent VTE, the prevalence of hypertension, diabetes mellitus, dyslipidemia, and alcohol intake was similar to that of control patients from the general population, suggesting limited benefits from screening these factors in young patients with VTE. Weight reduction and smoking cessation strategies are key targets for CVD prevention.</div></div>","PeriodicalId":100190,"journal":{"name":"Blood Vessels, Thrombosis & Hemostasis","volume":"2 2","pages":"Article 100059"},"PeriodicalIF":0.0,"publicationDate":"2025-02-06","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"","citationCount":null,"resultStr":null,"platform":"Semanticscholar","paperid":"143747947","PeriodicalName":null,"FirstCategoryId":null,"ListUrlMain":null,"RegionNum":0,"RegionCategory":"","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":"OA","EPubDate":null,"PubModel":null,"JCR":null,"JCRName":null,"Score":null,"Total":0}

{"title":"Dose-dependent effects of eltrombopag iron chelation on platelet formation","authors":"Elisabetta Bassi ,&nbsp;Vittorio Abbonante ,&nbsp;Alicia Aguilar ,&nbsp;Hana Raslova ,&nbsp;James B. Bussel ,&nbsp;Christian Andrea Di Buduo ,&nbsp;Alessandro Malara ,&nbsp;Alessandra Balduini","doi":"10.1016/j.bvth.2025.100060","DOIUrl":"10.1016/j.bvth.2025.100060","url":null,"abstract":"<div><h3>Abstract</h3><div>Iron deficiency is associated with thrombocytosis in patients, although thrombocytopenia can occur in cases of severe iron deficiency anemia. Eltrombopag (EP), a thrombopoietic agent approved for immune thrombocytopenia, also acts as an iron chelator. Our study demonstrates that megakaryocytes (MKs) exhibit an increased requirement for iron as they mature and acquire the ability to form proplatelets and release platelets. Although low EP concentrations maintain MK functions, high EP concentrations disrupt iron homeostasis, reducing proplatelet formation. Mechanistically, EP-dependent iron chelation impairs MK cytoskeletal dynamics, induces higher extracellular signal–regulated kinase 1/2 (ERK1/2) signaling, and reduces posttranslational glutathionylation of tubulin protein. Addition of exogenous iron or oxidized glutathione to high-dose EP-treated MKs counteracts the negative effect on iron status and ERK1/2 signaling, thereby rescuing proplatelet formation. Overall, these data reveal the complex role of iron status on MK cytoskeletal dynamics and platelet biogenesis and may explain the varied clinical manifestations of iron deficiency on platelet counts.</div></div>","PeriodicalId":100190,"journal":{"name":"Blood Vessels, Thrombosis & Hemostasis","volume":"2 2","pages":"Article 100060"},"PeriodicalIF":0.0,"publicationDate":"2025-02-06","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"","citationCount":null,"resultStr":null,"platform":"Semanticscholar","paperid":"143839110","PeriodicalName":null,"FirstCategoryId":null,"ListUrlMain":null,"RegionNum":0,"RegionCategory":"","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":"","EPubDate":null,"PubModel":null,"JCR":null,"JCRName":null,"Score":null,"Total":0}

{"title":"A nonactivating ITGB3 mutation in the β3 cytoplasmic region causes macrothrombocytopenia with an impaired αIIbβ3/RhoA pathway","authors":"Keiichi Nakata ,&nbsp;Keigo Akuta ,&nbsp;Takaya Endo ,&nbsp;Midori Koike ,&nbsp;Daisuke Motooka ,&nbsp;Daisuke Okuzaki ,&nbsp;Hisashi Kato ,&nbsp;Yoshiaki Tomiyama ,&nbsp;Naoki Hosen ,&nbsp;Hirokazu Kashiwagi","doi":"10.1016/j.bvth.2024.100036","DOIUrl":"10.1016/j.bvth.2024.100036","url":null,"abstract":"<div><h3>Abstract</h3><div>Almost all mutations of <em>ITGA2B</em> or <em>ITGB3</em> identified in congenital macrothrombocytopenia induce constitutive activation of αIIbβ3. However, whether concomitant αIIbβ3 activation is essential for macrothrombocytopenia development remains unknown. Recently, we identified the β3(R760C) mutation that does not induce αIIbβ3 activation in a patient with macrothrombocytopenia. The family study showed that macrothrombocytopenia with reduced expression of αIIbβ3 and glycoprotein IV (GPVI) appeared to be associated with patients heterozygous for β3(R760C). We generated β3(R760C) knockin (KI) mice and investigated the effects of the mutation on platelet/megakaryote biology. Macrothrombocytopenia was decreased to 76% and 40% of platelet counts in heterozygous (Hetero) and homozygous (Homo) KI mice, respectively, when compared with the wild-type mice. Platelet αIIbβ3 and GPVI expression were decreased in KI mice, and αIIbβ3 activation was not detected in nonstimulated KI platelets. Thus, the hetero KI mice reproduced the phenotype of the human participant, indicating that the β3(R760C) mutation is responsible for the macrothrombocytopenia. Platelet aggregation, agonist-induced JON/A binding, and P-selectin expression were impaired in KI mice. Platelet spreading on fibrinogen was also impaired in Homo mice with adenosine 5′-diphosphate or thrombin stimulation. Filopodia and lamellipodia formation was impaired in fibrinogen-adhered megakaryocytes of Homo mice with significantly impaired RhoA activation. Proplatelet formation in Homo mice was impaired with abnormal morphology. In addition, platelet life span was shortened in Homo mice. These data indicate that the β3(R760C) mutation impairs the inside-out and outside-in signaling of αIIbβ3, and abnormal actin rearrangement and impaired RhoA activation may play major roles in macrothrombocytopenia.</div></div>","PeriodicalId":100190,"journal":{"name":"Blood Vessels, Thrombosis & Hemostasis","volume":"2 1","pages":"Article 100036"},"PeriodicalIF":0.0,"publicationDate":"2025-02-01","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"","citationCount":null,"resultStr":null,"platform":"Semanticscholar","paperid":"143093714","PeriodicalName":null,"FirstCategoryId":null,"ListUrlMain":null,"RegionNum":0,"RegionCategory":"","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":"OA","EPubDate":null,"PubModel":null,"JCR":null,"JCRName":null,"Score":null,"Total":0}

{"title":"Podoplanin and microthrombi in lung injury","authors":"Jahnavi Gollamudi ,&nbsp;Ricardo Gonzalez Delgado ,&nbsp;Min Soon Cho ,&nbsp;Brianne Wharton ,&nbsp;Hani Lee ,&nbsp;Animesh Vadaparti ,&nbsp;Swapan K. Dasgupta ,&nbsp;Miguel A. Cruz ,&nbsp;Perumal Thiagarajan ,&nbsp;Vahid Afshar-Kharghan","doi":"10.1016/j.bvth.2024.100034","DOIUrl":"10.1016/j.bvth.2024.100034","url":null,"abstract":"","PeriodicalId":100190,"journal":{"name":"Blood Vessels, Thrombosis & Hemostasis","volume":"2 1","pages":"Article 100034"},"PeriodicalIF":0.0,"publicationDate":"2025-02-01","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"","citationCount":null,"resultStr":null,"platform":"Semanticscholar","paperid":"143093756","PeriodicalName":null,"FirstCategoryId":null,"ListUrlMain":null,"RegionNum":0,"RegionCategory":"","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":"OA","EPubDate":null,"PubModel":null,"JCR":null,"JCRName":null,"Score":null,"Total":0}

{"title":"Association of high γ′ fibrinogen levels with adverse events in patients with COVID-19","authors":"Queen Revollido ,&nbsp;Lydia Buzzard ,&nbsp;David X. Lee ,&nbsp;Matthew Strnad ,&nbsp;Scott McLoud ,&nbsp;Akram Khan ,&nbsp;William B. Messer ,&nbsp;David H. Farrell","doi":"10.1016/j.bvth.2025.100048","DOIUrl":"10.1016/j.bvth.2025.100048","url":null,"abstract":"","PeriodicalId":100190,"journal":{"name":"Blood Vessels, Thrombosis & Hemostasis","volume":"2 1","pages":"Article 100048"},"PeriodicalIF":0.0,"publicationDate":"2025-02-01","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"","citationCount":null,"resultStr":null,"platform":"Semanticscholar","paperid":"143349954","PeriodicalName":null,"FirstCategoryId":null,"ListUrlMain":null,"RegionNum":0,"RegionCategory":"","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":"OA","EPubDate":null,"PubModel":null,"JCR":null,"JCRName":null,"Score":null,"Total":0}